Cargando…

Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline

BACKGROUND: We evaluated Aβ misfolding in combination with Aβ(42/40) ratio as a prognostic tool for future clinical progression to mild cognitive impairment (MCI) or dementia due to Alzheimer’s disease (AD) in individuals with subjective cognitive decline (SCD). METHODS: Baseline plasma samples (n =...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stockmann, Julia, Verberk, Inge M. W., Timmesfeld, Nina, Denz, Robin, Budde, Brian, Lange-Leifhelm, Julia, Scheltens, Philip, van der Flier, Wiesje M., Nabers, Andreas, Teunissen, Charlotte E., Gerwert, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7761044/ https://www.ncbi.nlm.nih.gov/pubmed/33357241 http://dx.doi.org/10.1186/s13195-020-00738-8

Ejemplares similares

Correction to: Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer’s disease in individuals with subjective cognitive decline
por: Stockmann, Julia, et al.
Publicado: (2021)

Genetic predisposition, Aβ misfolding in blood plasma, and Alzheimer’s disease
por: Stocker, Hannah, et al.
Publicado: (2021)

Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline
por: Ebenau, Jarith L., et al.
Publicado: (2022)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Aβ misfolding in blood plasma is inversely associated with body mass index even in middle adulthood
por: Möllers, Tobias, et al.
Publicado: (2021)

Amyloid-β peptides in cerebrospinal fluid of patients with dementia with Lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2019)

Amyloid blood biomarker detects Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2018)

Aβ misfolding in blood plasma measured by immuno‐infrared‐sensor as an age‐independent risk marker of Alzheimer's disease
por: Möllers, Tobias, et al.
Publicado: (2021)

Grey matter network markers identify individuals with prodromal Alzheimer’s disease who will show rapid clinical decline
por: Pelkmans, Wiesje, et al.
Publicado: (2022)

ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project
por: Ebenau, Jarith L., et al.
Publicado: (2020)

Amyloid‐β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest‐old
por: Pelkmans, Wiesje, et al.
Publicado: (2021)

Subjective cognitive decline and self‐reported sleep problems: The SCIENCe project
por: Exalto, Lieza G., et al.
Publicado: (2022)

Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020)

Highly specific and ultrasensitive plasma test detects Abeta(1–42) and Abeta(1–40) in Alzheimer’s disease
por: Thijssen, Elisabeth H., et al.
Publicado: (2021)

Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021)

Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment
por: ten Kate, Mara, et al.
Publicado: (2017)

A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline
por: Verfaillie, Sander C. J., et al.
Publicado: (2018)

Amyloid-β Load Is Related to Worries, but Not to Severity of Cognitive Complaints in Individuals With Subjective Cognitive Decline: The SCIENCe Project
por: Verfaillie, Sander C. J., et al.
Publicado: (2019)

Pre‐amyloid stage of Alzheimer's disease in cognitively normal individuals
por: Tijms, Betty M., et al.
Publicado: (2018)

Aβ and tau structure-based biomarkers for a blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer's disease
por: Nabers, Andreas, et al.
Publicado: (2019)

Characteristics of subjective cognitive decline associated with amyloid positivity
por: Janssen, Olin, et al.
Publicado: (2021)

Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging
por: Leijenaar, Jolien F., et al.
Publicado: (2017)

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline
por: Verfaillie, Sander C.J., et al.
Publicado: (2016)

Misfolding and Amyloid Aggregation of Apomyoglobin
por: Iannuzzi, Clara, et al.
Publicado: (2013)

Visualizing the (Causal) Effect of a Continuous Variable on a Time-To-Event Outcome
por: Denz, Robin, et al.
Publicado: (2023)

Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status
por: Babapour Mofrad, Rosha, et al.
Publicado: (2021)

Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019)

Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020)

Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2017)

Declining functional connectivity and changing hub locations in Alzheimer’s disease: an EEG study
por: Engels, Marjolein MA, et al.
Publicado: (2015)

Correction to: Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline
por: Bos, Isabelle, et al.
Publicado: (2018)

Psychosocial Effects of Corona Measures on Patients With Dementia, Mild Cognitive Impairment and Subjective Cognitive Decline
por: van Maurik, Ingrid S., et al.
Publicado: (2020)

Sectoral segmentation of retinal amyloid imaging in subjects with cognitive decline
por: Dumitrascu, Oana M., et al.
Publicado: (2020)

Amsterdam Dementia Cohort: Performing Research to Optimize Care
por: van der Flier, Wiesje M., et al.
Publicado: (2018)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
por: Reimand, Juhan, et al.
Publicado: (2019)

Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease
por: Dicks, Ellen, et al.
Publicado: (2019)

Early Divergence in Misfolding Pathways of Amyloid‐Beta Peptides
por: Mamone, Salvatore, et al.
Publicado: (2021)

Slowing of Hippocampal Activity Correlates with Cognitive Decline in Early Onset Alzheimer’s Disease. An MEG Study with Virtual Electrodes
por: Engels, Marjolein M. A., et al.
Publicado: (2016)

Steeper memory decline after COVID-19 lockdown measures
por: Bakker, Els D., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ndlfkcf78uf5ua01dgmp4hp80t